Waters Corporation (WAT) Debt to Assets Ratio: 0.29%
The debt to assets ratio for Waters Corporation (WAT) is 0.29% as of Thursday, June 11, 2026.
WAT Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.29%
WAT Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Waters Corporation (WAT) | $23.21B | 0.29% |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 0.63% |
| BioNTech SE (BNTX) | $22.39B | 0.01% |
| Veeva Systems Inc. (VEEV) | $26.31B | 0.01% |
| Moderna, Inc. (MRNA) | $18.71B | 0.16% |
| DexCom, Inc. (DXCM) | $28.92B | 0.22% |
| Biogen Inc. (BIIB) | $28.94B | 0.24% |
| Hologic, Inc. (HOLX) | $16.97B | 0.29% |
| IQVIA Holdings Inc. (IQV) | $30.08B | 0.54% |
| Medline Inc. (MDLN) | $31.40B | 0.33% |
Leverage Ratios Comparison
Debt/Assets
0.3%
Debt/Equity
0.58
Current Ratio
1.73
Interest Coverage
17.6x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Waters Corporation Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Waters Corporation Debt to Assets Ratio FAQ
- What is the debt to assets ratio for Waters Corporation (WAT)?
- The debt to assets ratio for WAT stock is 0.29%.
About Waters Corporation
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Udit Batra